13,000 Shares in Insmed, Inc. $INSM Purchased by S&CO Inc.

Key Points

• S&CO Inc. purchased 13,000 Insmed shares worth approximately $1.39 million during the second quarter, adding to broader institutional interest in the biopharmaceutical company.
• Insmed insiders sold 294,440 shares valued at roughly $37.8 million over the past 90 days, while company insiders retain a 2.1% ownership stake.
• Analysts remain broadly bullish, with a consensus “Buy” rating and $205.52 price target. Insmed also exceeded quarterly EPS and revenue expectations, reporting $425.5 million in revenue, up 296.1% year over year.

S&CO Inc. purchased a new stake in shares of Insmed, Inc. (NASDAQ:INSM - Free Report) during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund purchased 13,000 shares of the biopharmaceutical company's stock, valued at approximately $1,386,000.

A number of other hedge funds and other institutional investors have also bought and sold shares of INSM. CIBC Private Wealth Group LLC grew its position in shares of Insmed by 42.1% in the 3rd quarter. CIBC Private Wealth Group LLC now owns 179 shares of the biopharmaceutical company's stock worth $26,000 after buying an additional 53 shares during the last quarter. EverSource Wealth Advisors LLC increased its stake in shares of Insmed by 10.2% during the fourth quarter. EverSource Wealth Advisors LLC now owns 747 shares of the biopharmaceutical company's stock valued at $130,000 after buying an additional 69 shares during the period. Private Advisor Group LLC lifted its stake in Insmed by 1.8% in the first quarter. Private Advisor Group LLC now owns 4,749 shares of the biopharmaceutical company's stock worth $777,000 after acquiring an additional 82 shares during the period. Glenmede Trust Co. NA lifted its stake in Insmed by 5.4% in the first quarter. Glenmede Trust Co. NA now owns 1,916 shares of the biopharmaceutical company's stock worth $313,000 after acquiring an additional 98 shares during the period. Finally, Allworth Financial LP boosted its holdings in Insmed by 20.5% in the fourth quarter. Allworth Financial LP now owns 635 shares of the biopharmaceutical company's stock valued at $111,000 after acquiring an additional 108 shares in the last quarter.

Insider Buying and Selling at Insmed

In related news, CFO Sara Bonstein sold 2,404 shares of the company's stock in a transaction that occurred on Wednesday, June 3rd. The stock was sold at an average price of $102.27, for a total value of $245,857.08. Following the sale, the chief financial officer owned 69,082 shares in the company, valued at $7,065,016.14. This represents a 3.36% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Michael Alexander Smith sold 6,149 shares of the firm's stock in a transaction that occurred on Friday, May 22nd. The shares were sold at an average price of $108.47, for a total value of $666,982.03. Following the transaction, the insider directly owned 41,613 shares of the company's stock, valued at approximately $4,513,762.11. This trade represents a 12.87% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 294,440 shares of company stock valued at $37,758,548 over the last ninety days. Company insiders own 2.10% of the company's stock.

Analyst Upgrades and Downgrades

Several research analysts have commented on INSM shares. UBS Group restated a "buy" rating and issued a $172.00 price objective on shares of Insmed in a report on Friday, August 7th. Truist Financial reaffirmed a "buy" rating and set a $195.00 target price (up from $185.00) on shares of Insmed in a research note on Monday, August 10th. Cantor Fitzgerald reiterated an "overweight" rating and set a $235.00 price target on shares of Insmed in a research report on Tuesday, July 28th. Jefferies Financial Group reissued a "buy" rating and issued a $175.00 price target on shares of Insmed in a research note on Thursday, August 6th. Finally, Wells Fargo & Company raised their price objective on shares of Insmed from $161.00 to $169.00 and gave the stock an "overweight" rating in a report on Friday, August 7th. Two research analysts have rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, Insmed presently has a consensus rating of "Buy" and a consensus target price of $205.52.

Insmed Stock Down 2.1%

NASDAQ:INSM opened at $123.74 on Friday. The company has a debt-to-equity ratio of 0.74, a current ratio of 3.72 and a quick ratio of 3.40. The firm's 50-day moving average price is $107.88 and its 200-day moving average price is $128.20. The company has a market capitalization of $27.02 billion, a PE ratio of -30.11 and a beta of 0.81. Insmed, Inc. has a 1-year low of $90.39 and a 1-year high of $212.75.

Insmed (NASDAQ:INSM - Get Free Report) last issued its quarterly earnings results on Thursday, August 6th. The biopharmaceutical company reported ($0.06) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.67) by $0.61. The company had revenue of $425.49 million during the quarter, compared to analysts' expectations of $395.50 million. Insmed had a negative net margin of 76.94% and a negative return on equity of 123.94%. Insmed's revenue was up 296.1% on a year-over-year basis. During the same period last year, the company posted ($1.70) EPS. On average, equities analysts predict that Insmed, Inc. will post -1.83 EPS for the current fiscal year.

About Insmed

Insmed Incorporated is a biopharmaceutical company focused on developing and commercializing therapies for patients with rare and serious diseases, with a particular emphasis on difficult-to-treat pulmonary infections. Headquartered in Bridgewater, New Jersey, the company concentrates its research and development efforts on targeted drug delivery technologies and novel formulations intended to improve clinical outcomes for patients who have limited treatment options.

The company's principal marketed product is ARIKAYCE (amikacin liposome inhalation suspension), an inhaled liposomal formulation of the antibiotic amikacin that is approved by the U.S.

Want to see what other hedge funds are holding INSM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Insmed, Inc. (NASDAQ:INSM - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source